Dear Industry Partner,
Increasing costs of modern medical modalities may generate substantial between interest of individuals and financial potential in a community.
At this Budapest meeting, cost-effectiveness of different liver diseases will be analysed by medical and health-economy experts to help physicians, insurance companies and decision makers in rational allocation of resources.
In addition to co-chairs professors Markus Peck-Radosavljevic (secretary general of EASL, Vienna, Austria) and Cihan Yurdaydin (educational councillor of EASL, Ankara, Turkey), other opinion leader hepatologist, including Professors Rafael Esteban (Barcelona, Spain), Graham Foster (London, UK),Christoph Sarrazin (Frankfurt, Germany) are invited to share their views on financial aspects of and cost-effectiveness in liver diseases.
Gabor Horvath, MD, (Budapest, Hungary)
Main topics include health benefit and cost-effectiveness of
– Treatment choices of esophageal varices
– Diagnostic algorythm of liver nodules
– Somatostatin versus terlipressin in acute variceal bleeding – medical/surgical th.- TIPs vs. on-demand tap in refractory ascites / treatment modelling
– Screening versus non-screening for HCC in non-viral cirrhosis
– IFN-based/IFN-free treatment versus observation in CHC with F 1-2 fibrosis
– IFN-based/IFN-free treatment versus observation in CHC with F 3-4 fibrosis
– IFN-based/IFN-free treatment versus observation pre- during – post livertransplant
– Survillance versus no survillance in HCV cirrhosis regressed to F2/F3 from F4 after SVR
– Birth-cohort screening for HCV in Europe
– Screening for HCV in acute IVD population / HIV coinfected population
– Vaccination against HBV at birth versus at age 12
– Vaccination against HBV for older people
– Entecavir versus tenofovir in decompensated HBV cirrhosis
- Entecarin versus tenofovir in compensated HBV cirrhosis
- IFN versus NA for HBV in non-cirrhotic patients
- Annual versus 6- monthly HBV-DNS on long term NA therapy
– Screening for HCC in decompensated or compensated HBV cirrhosis
– Screening for HCC in non- cirrhotic CHB on NA treatment